Nevertheless, our data consistently demonstrated a decreased number of PAX7+ cells in D233E patients, compared with healthy and disease controls, including secondary dystroglycanopathies. This evidence concerns the gene PAX7 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.